Celonic and CureVac announced agreement to manufacture over 100 million doses of CureVacﾒs COVID-19 vaccine CVnCoV
On Mar. 30, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacﾒs mRNA-based COVID-19…
Measles vaccine used as base for experimental COVID vaccine
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
Moderna announced shipment of 100 millionth dose of its COVID-19 vaccine to the U.S. Government
On Mar. 29, 2021, Moderna announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine…
GSK to manufacture Novavax’ COVID-19 vaccine
On Mar. 29, 2021, Novavax, GSK and the UK Government Vaccines Taskforce announced an agreement in principle to…
Johnson & Johnson announced agreement with African Vaccine Acquisition Trust for COVID-19 vaccine candidate
On Mar. 29, 2021, Janssen Pharmaceutica announced that it had entered into an agreement with the African Vaccine…
BioNTech updated on vaccine production status at Marburg manufacturing site
On Mar. 26, 2021, BioNTech announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19…
Biotechnology | HIV | Therapeutics | Vaccine
Oregon Health & Science University researchers unlocked HIV vaccine candidate’s mysteries 20 years later
On Mar. 25, 2021, about two decades after first devising a new kind of vaccine, Oregon Health &…
Virginia Tech and UVA virologists developed broadly protective coronavirus vaccines
On Mar. 24, 2021, Virginia Tech researchers announced that their candidate Coronavirus vaccines, prevented pigs from becoming ill…
Clover Biopharma and Dynavax announcd first participants dosed in phase 2/3 trial for COVID-19 vaccine candidate
On Mar. 24, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have were dosed in Clover’s…
CureVacﾒs COVID-19 vaccine candidate demonstrated protection against SARS-CoV-2 B1351 variant
On Mar. 23, 2021, CureVac announced publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protected…
CureVac expanded CVnCoV COVID-19 vaccine candidate clinical trial Aanalyses to include phase 2b/3 variant
On Mar. 22, 2021, CureVac announced plans to expand and further specify the protocols of its ongoing late-stage…
Investigational AstraZeneca vaccine prevented COVID-19
On Mar. 22, 2021, the NIH announced that results from a large clinical trial in the U.S. and…
US, Chile and Peru interim trial data showed Oxford-AstraZeneca vaccine was safe and highly effective
On Mar. 22, 2021, Oxford University announced that a Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted…
Moderna announced supply agreement with the Philippines for 7 million additional doses of COVID-19 Vaccine Moderna
On Mar. 22, 2021, Moderna announced that the Philippines had secured 7 million additional doses of COVID-19 Vaccine…
Existing vaccines may protect against the Brazilian coronavirus variant
On Mar. 19, 2021, Scientists at the University of Oxford released pre-print data measuring the level of antibodies…
COVID-19 | Pharmaceutical | Vaccine | WHO
WHO COVID-19 subcommittee announced safety signals related to AstraZeneca COVID-19 vaccine
On Mar. 17, 2021, the WHO reported that the AstraZeneca COVID-19 vaccine (including Covishield) continued to have a…
Tonix Pharma reported positive COVID-19 vaccine efficacy results in non-human primates vaccinated with TNX-1800
On Mar. 17, 2021, Tonix Pharma announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
Altasciences partnered with NRC of Canada to qualify quantitative serological assay for detection of SARS-CoV-2 IgG antibodies
On Mar. 17, 2021, Altasciences working with the National Research Council of Canada (NRC), announced that it had…
Roche launched SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
On Mar. 16, 2021, Roche announced the launch of the cobasﾮ SARS-CoV-2 Variant Set 1 Test to detect…
Research highlighted risks of separating newborns from mothers during COVID-19 pandemic
On Mar. 16, 2021, research from the WHO and partners showed that the COVID-19 pandemic was severely affecting…
Moderna announced participants dosed in phase 2/3 study of COVID-19 vaccine in pediatric population
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
ImmunityBio announced positive interim phase I safety data of hAd5 T-cell COVID-19 vaccine candidate
On Mar. 15, 2021, ImmunityBio announced it had met the safety requirements for the first 12 participants in…
First participants dosed in Moderna phase 1 study evaluating mRNA-1283 next generation COVID-19 vaccine
On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study…
Altimmuneﾒs single dose, intranasal COVID-19 vaccine candidate prevented SARS-CoV-2-induced disease
On Mar. 15, 2021, Altimmune announced additional preclinical data for its single dose intranasal COVID-19 vaccine candidate, AdCOVID….
WHO added Janssen vaccine to list of safe and effective emergency tools against COVID-19
On Mar. 12, 2021, the WHO listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for…
Johnson & Johnson single-shot COVID-19 vaccine granted Emergency Use Listing by the WHO
On Mar. 12, 2021, Johnson & Johnson announced that the World Health Organization (WHO) had issued Emergency Use…
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
Altimmune expanded AdCOVID manufacturing collaboration with Lonza
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under…
Novavax confirmed ligh levels of efficacy against original and variant COVID-19 strains in UK and South Africa trials
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
Johnson & Johnson announced single-shot COVID-19 vaccine candidate received positive CHMP opinion
On Mar. 11, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…